abiraterone-acetate and Hypothyroidism

Abiraterone acetate (AA) is a selective oral inhibitor of Steroid-17α-Hydroxylase, for patients with castration-resistant prostate cancer. Not all patients respond to therapy, however, there are no biomarkers predicting response to AA therapy. The aim of the present study was the identification of a biomarker for patients who are likely to respond to AA therapy.. We measured thyroid parameters in a collective of 30 patients before and during AA therapy. For statistical analyses, paired and unpaired t-tests were used.. During AA therapy, responders developed a significant increase in thyroid stimulating hormone (TSH) compared to non-responders (p=0.03). In the subgroup of responders, 16 out of 21 patients (76.1%) had a significant increase in TSH level (p=0.001), suggesting that TSH increase is predictive of therapy response. Non-responders showed no change in TSH level during AA therapy.. Hypothyreosis may serve as a simple predictive biomarker for therapy response under AA therapy.

Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Biomarkers, Pharmacological; Bone Neoplasms; Follow-Up Studies; Humans; Hypothyroidism; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Thyrotropin